Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients

Schroth W, Buettner FA, Kandabarau S, Hoppe R, Fritz P, Kumbrink J, Kirchner T, Brauer HA, Ren Y, Henderson D, Madden SF, Sauer G, Fehm T, Wallwiener D, Fasching P, Muerdter T, Schwab M, Brauch H (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Clinical Cancer Research American Association for Cancer Research

Book Volume: 26

Pages Range: 6523-6534

Journal Issue: 24

DOI: 10.1158/1078-0432.CCR-20-1923

Abstract

Purpose: Patients with estrogen receptor- and/or progesterone receptor-positive, early breast cancer benefit from hormonal treatment, yet high global death burdens due to high prevalence and long-term recurrence risk call for biomarkers to guide additional treatment approaches.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Robert-Bosch-Krankenhaus DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) NanoString Technologies, Inc. US United States (USA) (US) Royal College of Surgeons in Ireland (RCSI) IE Ireland (IE) Heinrich-Heine-Universität Düsseldorf DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE)

How to cite

APA:

Schroth, W., Buettner, F.A., Kandabarau, S., Hoppe, R., Fritz, P., Kumbrink, J.,... Brauch, H. (2020). Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. Clinical Cancer Research, 26(24), 6523-6534. https://doi.org/10.1158/1078-0432.CCR-20-1923

MLA:

Schroth, Werner, et al. "Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients." Clinical Cancer Research 26.24 (2020): 6523-6534.

BibTeX: Download